Products

SignalHF
Implicity
Cardiology AI
SignalHF by Implicity is an FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care.
Implicity ILR ECG Analyzer
Implicity
Cardiology AI
Implicity's AI-powered platform provides smart remote monitoring solutions for cardiac implantable electronic devices (CIEDs) and implantable loop recorders (ILRs), enhancing arrhythmia detection and optimizing clinical workflows.

See all 2 products →

About Implicity

Implicity is a leading healthcare AI company that specializes in transforming cardiac remote monitoring. Their platform is designed to aggregate, normalize, and standardize data from all types of implantable cardiac electronic devices (CIEDs) across various manufacturers, as well as heart failure monitoring systems. This unified approach eliminates the need for clinicians to navigate multiple, disparate systems, thereby streamlining workflows and reducing administrative burden.

For physicians, Implicity’s AI-driven solutions offer significant advantages. The platform utilizes advanced algorithms to analyze vast amounts of cardiac data, identify clinically relevant events, and reduce false alarms, such as an 85% reduction in atrial fibrillation alert fatigue. This allows care teams to focus their attention on urgent cases, accelerate diagnoses, and provide more proactive and personalized patient care. Implicity also develops predictive AI algorithms, including SignalHF, which can assess a patient’s risk of worsening heart failure, enabling earlier intervention and potentially preventing hospitalizations.

Focus Areas

AI-driven remote cardiac monitoring cardiac implantable electronic device (CIED) data management heart failure prediction workflow automation false positive alert reduction clinical decision support digital health MedTech

Business Intelligence

TechnologyCloud-based, AI-driven platform that aggregates, normalizes, and analyzes data from all major cardiac device manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic, etc.) and integrates with EHRs. Utilizes machine learning and proprietary algorithms for alert management and predictive analytics.

What Physicians Need to Know

Remote Cardiac Monitoring
Implicity offers a universal, AI-driven platform that consolidates data from all five major cardiac implantable electronic device (CIED) manufacturers into a single interface. This streamlines the review process for physicians and care teams.
AI-Based Algorithms
Implicity utilizes FDA-cleared AI algorithms to filter out noise and reduce false positives. Their ILR ECG Analyzer can reduce false positives by up to 79% in ILR ECG recordings while maintaining high sensitivity. The AF Alert Management algorithm leads to an 85% decrease in unnecessary Atrial Fibrillation burden alerts.
Heart Failure Management
The SignalHF algorithm, an FDA-cleared AI-based tool, forecasts the risk of heart failure hospitalization by continuously analyzing physiological data trends to identify early warning signs of cardiac decompensation.
Predictive Medicine
Implicity's platform leverages AI to proactively identify high-risk patients, such as those predicted for heart failure hospitalization, enabling earlier intervention.
Clinical Workflow Optimization
The platform automates manual processes, such as billing workflows and reporting, and provides real-time access to patient data from anywhere. This has been shown to increase clinic productivity by 84% within two years.
Key Differentiators
Implicity's key differentiators include their FDA-cleared AI algorithms, the ability to deliver vast amounts of discrete data, and a universal platform that integrates data from all major CIED manufacturers. Their platform is associated with a 26% reduced mortality and 4% reduction in hospitalization length compared to conventional remote monitoring.
Technology Stack
Implicity's platform is cloud-based, eliminating the need for software installation or updates, and ensuring users always have the latest version. It is designed with an intuitive interface and guarantees secure access and data encryption, compliant with EU data privacy regulations and HIPAA.
Physician Tip

For physicians, Implicity's platform offers focused remote monitoring with fewer false alerts, enabling faster and more confident decision-making. The AI-driven insights help in proactively identifying high-risk patients, especially for heart failure, and significantly reduce alert fatigue by filtering out non-actionable data. The universal platform centralizes all CIED data, simplifying clinical review and allowing more time to be spent on critical patient management. The proven clinical impact, including reduced mortality and hospitalizations, provides strong evidence for improved patient outcomes.

Implicity's platform is designed for interoperability, centralizing and standardizing data from all major cardiac implantable electronic device manufacturers (Medtronic, Biotronik, Abbott, Boston Scientific, etc.). They also offer flexible solutions, allowing clinics to use their software with internal staff or outsource technical review to certified IDTF partners for a full solution, which can optimize billing and operational efficiency.

Products by Implicity

2 products in the directory

SignalHF
Implicity
Cardiology AI
SignalHF by Implicity is an FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care.
Implicity ILR ECG Analyzer
Implicity
Cardiology AI
Implicity's AI-powered platform provides smart remote monitoring solutions for cardiac implantable electronic devices (CIEDs) and implantable loop recorders (ILRs), enhancing arrhythmia detection and optimizing clinical workflows.

What the Web Says

Implicity is a remote cardiac monitoring platform that uses AI algorithms to unify, analyze, and streamline data from cardiac implantable electronic devices (CIEDs). The platform aims to enhance patient care, staff productivity, and billing compliance, and is used by cardiologists, electrophysiology nurses, clinic staff, and billing teams. Implicity's platform is associated with a 26% reduced mortality and 4% reduction in hospitalization length compared to conventional remote monitoring. While there is limited information on G2 and Capterra specifically for "Implicity" as a healthcare IT product, there are some employer reviews on Indeed.com for "Implicity Management" and "implicity" (software development company).

Overall: Positive

Strengths

  • Device-agnostic remote cardiac monitoring platform.
  • Aggregates and normalizes data from major CIED manufacturers.
  • Provides FDA-cleared AI algorithms for alert triage and workflow automation.
  • Supports both remote monitoring and in-clinic checks.
  • Associated with reduced mortality and hospitalization length.
  • Integrates with Epic EHR for improved workflows.

Limitations

  • Limited product reviews available on G2 and Capterra for the healthcare IT platform.
  • Some employer reviews for related companies (Implicity Management) mention issues in accounting.
  • Difficulty in finding comprehensive reviews specifically for the healthcare IT product across all requested platforms.

Based on reviews from: Elion, Implicity.com, Becker's Hospital Review, Indeed.com

Last updated: 2026-10-23

Videos

News, demos, and interviews about Implicity.

Loading videos...

Videos load interactively. If none appear, search YouTube for Implicity →

View all on YouTube

Press & Coverage

GlobeNewswire
Implicity's Next-Generation ILR ECG Analyzer Earns FDA Clearance
Implicity announced FDA 510(k) clearance for its next-generation ILR ECG Analyzer, a cloud-based AI software designed to reduce false-positive alerts from implantable cardiac monitors across all major device manufacturers. This marks the company's third FDA clearance.
2026-07
MobiHealthNews
Implicity raises $40M for AI remote cardiac monitoring
Implicity secured $40 million in funding to expand its U.S. commercial workforce, grow its European presence, and further invest in AI development, particularly for heart failure prediction algorithms.
2026-09
Pulse 2.0
Implicity Raises $40 Million To Expand AI Cardiac Remote Monitoring Platform
This article details Implicity's $40 million funding round, highlighting its universal platform that aggregates data from multiple cardiac devices and integrates with EHRs to streamline workflows and prioritize clinically important information.
2026-09
PR Newswire
Implicity Earns FDA Clearance for New Heart Failure Prediction Algorithm
Implicity received FDA 510(k) clearance for SignalHF, a machine learning algorithm that analyzes data from remotely monitored cardiac devices to assess a patient's risk of worsening heart failure, enabling earlier intervention.
2024-05
GlobeNewswire
Study Shows Implicity's New Agnostic Cloud-Based AI Algorithm Further Reduces False Alerts Even After Manufacturer AI Filtering in Modern Devices
New data presented at HRS 2026 demonstrated that Implicity's next-generation ILR ECG Analyzer significantly reduces false-positive alerts even after manufacturer AI filtering, maintaining high sensitivity and reducing clinician workload.
2026-04
AIPressRoom
Implicity Raises €35M to Expand US Operations
This article discusses Implicity's €35 million funding round, emphasizing its use for international expansion, particularly in the USA, and further development of its AI capabilities and heart failure prediction algorithms.
2026-09
Tech Funding News
Implicity raises €35M from IRIS and Five Arrows to scale AI that cuts cardiac deaths by 26%
Implicity secured €35 million in growth funding, with IRIS and Five Arrows as lead investors, to expand in the US and explore acquisition opportunities, noting the platform's association with a 26% reduction in patient mortality.
2026-09
Cardiovascular Business
FDA clears AI software for limiting false-positive ICM alerts
Implicity received its third FDA clearance for cloud-based AI software that reduces false-positive alerts from implantable cardiac monitors across various manufacturers, aiming to mitigate a major workflow obstacle for clinicians.
2026-07

Frequently Asked Questions

Implicity offers a cloud-based, AI-driven platform that unifies data from all major cardiac implantable electronic device (CIED) manufacturers into a single view, streamlining the review process. Its FDA-cleared AI algorithms, such as the ILR ECG Analyzer and AF Alert Management, significantly reduce false positive alerts by up to 79% and unnecessary AF alerts by 85%, allowing physicians to focus on clinically relevant events and optimize their workflow.
Implicity provides FDA-cleared AI algorithms like the ILR ECG Analyzer for arrhythmia detection, which reduces false positives in implantable loop recorder (ILR) ECGs by 79% while maintaining 99% sensitivity. For heart failure management, their SignalHF algorithm predicts heart failure hospitalizations within 30 days by analyzing physiological and device data, enabling proactive interventions and improved patient outcomes.
Implicity's platform optimizes clinical workflows by automating routine tasks, simplifying CIED alert management, and providing real-time access to patient data. It integrates with Electronic Health Record (EHR) systems like Epic via a SMART on FHIR app, ensuring seamless data flow and reducing the burden of manual data transfers for clinic staff and IT teams.
Implicity's solutions are FDA-cleared, including their AI algorithms like SignalHF and ILR ECG Analyzer. The platform is also fully compliant with data privacy regulations such as HIPAA and GDPR, and holds ISO 27001 and Health Data Hosting (HDS) certifications, ensuring high standards of data security and protection.
Yes, Implicity's platform is device-agnostic and designed to aggregate and standardize data from all major CIED manufacturers, including Abbott, Biotronik, Boston Scientific, Medtronic, and MicroPort. It also integrates with EHR systems through a SMART on FHIR application, ensuring interoperability and a unified view of patient data within existing hospital IT infrastructure.
Implicity provides comprehensive customer support, including a dedicated Customer Success team for onboarding, training, hotline assistance, and ongoing guidance to maximize platform utilization. They also engage in strategic partnerships, such as a distribution agreement with MicroPort CRM and collaborations with companies like Withings for heart failure solutions, to expand their reach and enhance their offerings.
Founded in 2016 by a cardiac electrophysiologist, Implicity has demonstrated strong growth, monitoring over 70,000 patients across more than 100 medical facilities in the US and Europe. The company secured $23 million in Series A funding in April 2022, bringing its total funding to $28 million, which is being used to accelerate international expansion and further develop its AI-based medical algorithms, indicating a stable and growth-oriented future.

Investors

Who's funded Implicity.

Related Companies

TimeDoc Health is a healthcare technology and services company that provides virtual care management solutions, primarily focusing on chronic care management (CCM), remote patient monitoring (RPM), and behavioral health integration (BHI). Their platform and services are designed to help healthcare organizations, including primary care providers, health systems, FQHCs (Federally Qualified Health Centers), and Medicare Advantage […]

Koios Care is a neurology-focused digital medicine company based in Antwerp, Belgium, specializing in AI-powered platforms. The company aims to revolutionize the management of neurological and chronic conditions, with an initial focus on Parkinson’s Disease. Koios Care’s platform utilizes everyday devices like smartphones and smartwatches to passively collect and analyze data, transforming it into objective, […]

CureCompanion is a healthcare technology company that specializes in virtual care solutions, offering an integrated platform of hardware and software for telemedicine. Their technology goes beyond basic video conferencing, enabling healthcare providers to conduct comprehensive virtual examinations. This includes the ability to examine skin, eyes, ears, and throat using HD cameras, listen to heart and […]

Caption Health, formerly known as Bay Labs and now part of GE HealthCare, is a pioneering medical artificial intelligence (AI) company dedicated to expanding access to high-quality ultrasound examinations. The company’s core offering is the Caption AI platform, which utilizes AI to guide healthcare providers, including those without extensive specialized training, in acquiring and interpreting […]

Anumana is an AI-driven health technology company dedicated to transforming cardiovascular care. Co-founded by nference and Mayo Clinic, Anumana develops software-as-a-medical-device (SaMD) solutions that leverage multimodal AI to support early detection, clinical decision-making, and intraoperative guidance across the continuum of care. The company’s portfolio includes FDA-cleared ECG-based algorithms, generative imaging applications, and real-time procedural support […]

Keya Medical Technology Co. is an international medical technology company specializing in deep learning-based AI solutions for non-invasive disease diagnosis and treatment. The company, founded in 2016, develops AI-enabled diagnostic devices that aim to enhance efficiency, accuracy, and precision in healthcare across various specialties, including cardiology, neurology, pulmonology, pathology, and surgery. [2, 4, 8, 14] […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.